The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Open accessAbstract
Background Sickle cell anaemia (SCA) is associated with significant morbidity from acute complications and organ dysfunction beginning in the first year of life. In the first multicenter randomised double-blinded trial in very young children with SCA, the impact of hydroxyurea (hydroxycarbamide) therapy on organ dysfunction, clinical complications, and laboratory findings, and its toxicity, were examined. Methods Eligible subjects had HbSS or Sβ0thalassaemia, were age 9–18 months at randomisation, and were not selected for clinical severity. Subjects received liquid hydroxyurea, 20 mg/kg/day, or placebo for two years. Primary study endpoints were splenic function (qualitative uptake on 99Tc spleen scan) and renal function (glomerular filtration rate by 99mTc-DTPA clearance). Additional evaluations included: blood counts, HbF, chemistry profiles, spleen function biomarkers, urine osmolality, neurodevelopment, transcranial Doppler ultrasonography, growth, and mutagenicity. Study visits occurred every two to four weeks. Findings Ninety-six subjects received hydroxyurea and 97 placebo; 86% completed the study. Significant differences were not seen for the primary endpoints, but suggestive benefit was noted in quantitative measures of spleen function. Hydroxyurea significantly decreased pain and dactylitis with trends for decreased acute chest syndrome, hospitalisation and transfusion. Hydroxyurea increased haemoglobin and HbF and decreased WBC count. Toxicity was limited to mild-moderate neutropaenia. Interpretation Although hydroxyurea treatment did not reduce splenic and renal dysfunction assessed by primary endpoint measures, it resulted in major clinical benefit because of diminished acute complications, favorable haematologic results, and a lack of unexpected toxicities. Based on the safety and efficacy data from this trial, hydroxyurea can now be considered for all very young children with SCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, all children seem to have a robust HbF response to hydroxyurea that retards the natural age-related fall in HbF.87”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Prediction of Adverse Outcomes in Children with Sickle Cell Disease
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420203 · Cited by 508
Self-citationThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Self-citationVoskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 406
Self-citationZimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., & Ware, R. E. (2003) · Blood · doi:10.1182/blood-2003-07-2475 · Cited by 312
Self-citationSystematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease
Lanzkron, S., Strouse, J. J., Wilson, R. F., Beach, M. C., Haywood, C., Park, H., Witkop, C., Bass, E. B., & Segal, J. B. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-12-200806170-00221 · Cited by 288
Cited by
Sorted by citations
Items 701–796 of 796
Hematopoietic Cell Transplantation for Sickle Cell Disease
Walters, M. C. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch72
Present and Future Strategies with Curative Intent for Hereditary Hemoglobinopathies
Oliveira, V. G., Saraiva, A. F., Costa, F., & de Sousa, A. B. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1903086
Immunogenetics in sickle cell disease
Tozatto‐Maio, K. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-17122019-151356
Shaw, R. S., Kappa, S. S., & Nickel, R. S. (2019) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001638
Brown, A. B. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.sicklecell_overview
Treatment of “Other” Stroke Etiologies
Kasner, S. E., & Cucchiara, B. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29544-4.00056-6
Menon, N., & Frei‐Jones, M. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-49980-8_5
Team DFTB (2020) · Don't Forget The Bubbles · doi:10.31440/dftb.27598
70 The Effect of Rapid COVID-19 Testing on Emergency Department Throughput
Supat, B., Castillo, E. M., Brennan, J., & Kreshak, A. A. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2020.09.080
To Study the Effect of Hydroxyurea on Frequency of Blood Transfusion in Sickle Cell Anemia
Joshi, D. S., & Chaube, D. (2020) · Scholars Journal of Applied Medical Sciences · doi:10.36347/sjams.2020.v08i08.026
Medication Induced Cardiotoxicity and Skin Reactions
Sălăvăstru, C., Cretu, S., Sendrea, A. M., & Ţiplica, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-54779-0_21
de Montalembert, M., & Allali, S. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-76049-5.00027-8
Hyacinth, H. I., & Adams, R. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-56210-0_9
Multigrid Methods based on improved Coarse Grid Correction Techniques
Zubair, B. H. (2009)
Hardit, V., Alvarez, O. A., Ziga, E. D., & Alperstein, W. (2022) · Pediatric Annals · doi:10.3928/19382359-20211211-01 · Cited by 1
Hemostatic Aspects of Sickle Cell Disease
Ataga, K. I., & Lottenberg, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00041-8
Kirkham, F. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00035-7
Newborn screening for sickle cell disease: necessary but not sufficient
Wang, W. C. (2015) · Jornal de Pediatria (Versão em Português) · doi:10.1016/j.jpedp.2015.03.014
Self-citationBrousse, V. A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-76049-5.00018-7
Schifferli, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48103-5_4
Inusa, B. P. D. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718883904.793549707
The Lung in Sickle Cell Disease
Greenough, A., & Knight‐Madden, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44887-1.00062-6
Improved Outcomes With L-Glutamine Use in Sickle Cell Disease
(2018) · AAP Grand Rounds · doi:10.1542/gr.40-4-40
Janson, I. A., Bloom, E., Hampton, K. C., Meier, E. R., Rampersad, A. G., & Kronenberger, W. G. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s387227
Taylor, J. (2022) · Springer eBooks · doi:10.1007/978-3-030-96542-6_58
Avaliação de prescrições pediátricas de hidroxiureia para pacientes com doença falciforme
Duque, F. A. T., Dias, E. F., Malta, J. S., Rodrigues, P. C., Braga, L. D. F. M., & da Costa, J. M. (2022) · O Mundo da Saúde · doi:10.15343/0104-7809.202246369379p
Evaluation of pediatric hydroxyurea prescriptions for patients with sickle cell disease
Duque, F. A. T., Dias, E. F., Malta, J. S., Rodrigues, P. C., Braga, L. D. F. M., & da Costa, J. M. (2022) · O Mundo da Saúde · doi:10.15343/0104-7809.202246369379i
Neonatal Erythrocyte Disorders
CARLBERG, K. (2023) · Avery's Diseases of the Newborn · doi:10.1016/b978-0-323-82823-9.00069-6
Omodele, D., Edge, D., & Crawford, D. A. (2023) · doi:10.1002/9781119819653.ch37
Aboluwarin, A., Ojuawo, A., Akanbi, O., Quadri, L., Elukpo, H., Oloko, A. G. Y., & Ernest, K. (2023) · Open Journal of Pediatrics · doi:10.4236/ojped.2023.136089
The Spleen and Sickle Cell Anemia
Al-Salem, A. H. (2023) · Springer eBooks · doi:10.1007/978-981-99-6191-7_21
Approach to the Diagnosis and Management of Essential Thrombocytosis in a Resource-Limited Setting
Onyango, V. C., Theuri, A. W., Gachie, S. M., Malalu, C. P., & Fryda, W. C. (2024) · American Journal of Medical Science and Innovation · doi:10.54536/ajmsi.v3i1.2312
Sickle cell disease: causes, treatments and the patient experience
Spurway, A., George, S., Thompson, C., Weeks, S., & Teo, X. Y. (2024) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2023.1.205570
Oluwole, O. B., Ampomah, M. A., Owusu-Ansah, A. T., Nouraie, M. S., Segbefia, C. I., & Novelli, E. M. (2024) · doi:10.22541/au.170667427.77137053/v1
Enuresis and Hyperfiltration in Children with Sickle Cell DiseasePreprint
Zahr, R. S., Ding, J., Kang, G., Wang, W. C., Hankins, J. S., Ataga, K. I., Lebensburger, J. D., & Porter, J. S. (2024) · doi:10.22541/au.170667006.62479611/v1
Self-citationUpdate in Pediatric Hematology
Solh, Z., Chan, A. K. C., & Bhatt, M. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-41542-5_17
Kuo, K. H. M., Faller, A. D., Lavelle, D., Saunthararajah, Y., & Perrine, S. P. (2024) · Medical Research Archives · doi:10.18103/mra.v12i3.5130
Sunmonu, N. A., Adams, R. J., Karkoska, K. A., & Hyacinth, H. I. (2024) · Springer eBooks · doi:10.1007/978-3-031-41777-1_4
Sánchez, L. M., Morrone, K. A., Frei‐Jones, M. J., & Fasipe, T. (2024) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002869
Cardiopulmonary Complications of Sickle Cell Disease in Children
Santiago, M. T., Feld, L. M., Dhar, A., Christian-Weekes, L. N., Appiah‐Kubi, A., Mitchell, E., Aygün, B., & Fiorino, E. K. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005507
Wu, X., Stratford, J. K., Kesler, K. L., Ives, C. L., Hendershot, T. P., Kroner, B. L., Qin, Y., & Pan, H. H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.15.608203
Mahesri, M., Lee, S. B., Levin, R., Imren, S., Zhang, L., Beukelman, T., Titievsky, L., & Desai, R. J. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3449
Kirkham, F. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00043-1
Lemanek, K. L., Iskander, J. M., Stanek, J. R., & Creary, S. E. (2024) · Journal of Pediatric Neuropsychology · doi:10.1007/s40817-024-00168-6
PIVOTing the Course of HbSC Disease
Appiah‐Kubi, A., & Aygün, B. (2025) · NEJM Evidence · doi:10.1056/evide2400449
Elalfy, M. S., Ismail, E. A. R., Makkeyah, S. M. M., Samir, A., Salama, D. H., Eldin, N. M. S., ElMaghraby, D. M. F., Gad, N. A., Ali, M. F. B., & Ebeid, F. S. E. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2495670
Clinical consultation: The pharmacist’s role in hydroxyurea management for sickle cell disease
Roessner, C., Uminski, K., Goodyear, D. M., & Rydz, N. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf114
NO (nitric oxide) to priapism with hydroxyurea and tadalafil
Ataga, K. I. (2025) · Blood · doi:10.1182/blood.2025028905
Anti-sickling efficacy and safety of Sailin-HbS, an indigenous Ayurvedic formulation
Bhatt, S., Bhansali, A., Rajesh, A. S., Meher, S., Jena, R. K., Dash, B. P., Panda, P. K., Gupta, K., & Kundu, S. (2025) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2025.102956
Impact of hydroxyurea on pediatric sleep in sickle cell disease
Yoo, M., Bai, S., Kalmus, G., Abel, L., Dampier, C., Gillespie, M. L., Vala, S., Huang, T., Khemani, K., Leu, R. M., et al. (2025) · Blood Red Cells & Iron · doi:10.1016/j.brci.2025.100026
Hydroxyurea for Children with Sickle Cell Disease
Coyne, F. W., & Strouse, J. J. (2025) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2025.08.007
Hildenbrand, A. K., Pitone, M. L., Bear, B., Schultz, C. L., Finch, S., Morley, D., Hubbard, S., Decino, A., Alderfer, M. A., Crosby, L. E., et al. (2025) · Journal of Medical Extended Reality · doi:10.1177/29941520251374284
Platt, M. O., Lee, H. S., & Hatoum, L. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_11 · Cited by 1
Knight, L. M. J., Tanabe, P. J., Blewer, A. L., Goodrich, J., King, A. A., Reuter‐Rice, K., & Crego, N. (2025) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoaf038
Epidemiological and clinical profile of sickle cell disease in a series of Moroccan children
Arbai, K., Ismaili, F. Z. A., Zian, Z., Bali, M. E., Mansour, C., Lhoussni, A., Belahsen, S., Nourouti, N. G., Barakat, A., & Mechita, M. B. (2025) · Journal of Community Genetics · doi:10.1007/s12687-025-00850-y
Dain, A. S., Li, Y., Master, S., Bailey, C. L., Vossough, A., Ichord, R., Raffini, L. J., Getz, K., & Kwiatkowski, J. L. (2025) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2025.2579978
Mukhopadhyay, A., Smeltzer, M. P., Dudley, J., Badawy, S. M., Mathias, J. G., Plaxco, A. P., Ray, M. A., Wiese, A. D., Stevens, W. I., Gurney, J. G., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693126
Meier, E. R., Creary, S. E., Heeney, M. M., Dong, M., Appiah‐Kubi, A., Nelson, S. C., Niss, O., Piccone, C. M., Quarmyne, M.-O., Quinn, C. T., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13297152
Khargekar, N. C., Banerjee, A., Athalye, S., Mahajan, N., Kargutkar, N., Tapase, P., & Madkaikar, M. R. (2024) · Figshare · doi:10.6084/m9.figshare.26678726
Sickle Cell Disease: Treatment Options of the Past, Present, and Future
Jacobs, C., & Liu, A. (2025) · AJN American Journal of Nursing · doi:10.1097/ajn.0000000000000216
Low Use of FDA ‐Approved Medications for Sickle Cell Disease in Adults
Rivenbark, J. G., Kinlaw, A. C., Trogdon, J. G., & Little, J. A. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70107
Steinberg, M. H. (2026) · Springer eBooks · doi:10.1007/978-3-031-96019-2_34
Hemorheology, pathophysiology, and current treatment of sickle cell disease: A minireview
Maruyama, T., Hieda, M., & Fujino, T. (2025) · Journal of Biorheology · doi:10.17106/jbr.39.2
Adding to the Sickle Cell Disease Burden: Rising Hydroxyurea Costs Demand Action
Rush, C., Creary, S. E., Crabtree, M., & Crabtree, T. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70159
Fluid mechanics of thin blood films to detect anemia and sickle cell disease
Mir, M. A., Tirumkudulu, M. S., & Raicha, B. (2026) · Lab on a Chip · doi:10.1039/d5lc00943j
Systematic literature review on hydroxyurea treatment of SCD in low- to middle-income countries
Paintsil, V., Marfo, K., Khan, S., Egbujo, O. A., & Tshilolo, L. M. (2026) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoag018
Immunogénétique en drépanocytose
Tozatto‐Maio, K. (2019) · theses.fr (ABES) · doi:10.70675/92d0b87bz2afdz446dza5bdze7321b6555d7
Brousse, V. A. M. (2018) · theses.fr (ABES) · doi:10.70675/25847085z217dz4270z9ae1za20faba3e022
Facteurs psychosociaux influençant l’observance thérapeutique des adultes atteints de drépanocytose
Doglioni, D. O. (2021) · theses.fr (ABES) · doi:10.70675/9897b5b1z2953z487cza41aza3d226b9216f
Temiye, E., Akinsete, A. M., Joacquim, A. O., Fakile, U. O., Ashefor, O., Ogamba, C. F., Ogbenna, A. A., Adeyemo, N., Okodugha, O., Edokpolo, E., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70399
Stauffer, É. (2021) · doi:10.70675/65143700zc6e4z45e0z8273z3a91bb022450
Sickle Cell Disease: Implications for Underserved Populations
Sobota, A. E., & Edwards, J. G. (2026) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610028493-ch19
Azul, M., Okhomina, V. I., Kang, G., Jacobs, T. W., Lebensburger, J. D., Zahr, R. S., & Rai, P. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100085
Sickle Cell Disease: Outpatient Management Issues
Oluwole, O. B., & Novelli, E. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-13858-3_13
Izuegbuna, O. (2026) · Qeios · doi:10.32388/uh2l2u
Peprah, E., Gyamfi, J., Kanneh, N., Hameed, T., Onakomaiya, D. O., Ahmed, N., Billett, H., Campbell, A., Cohen, A., Easterling, T., et al. (2026) · Frontiers in Health Services · doi:10.3389/frhs.2026.1842019
Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease
Musallam, K. M., & Andemariam, B. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2682386
Biomarker profiles in distinct clinical subphenotypes of SCD: an explorative study
Hoving, V., van Berkel, M., Donker, A. E., Swinkels, D. W., & Schols, S. E. M. (2026) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoag028
Evans, M. D., Abdoli, S., Skeens, M. A., Bulgin, D., & Lindley, L. C. (2026) · Journal of Pediatric Hematology/Oncology Nursing · doi:10.1177/27527530261448518
Alvarez, O. A., Lerebours, E., Hanna, M. P., Fleur, R. S., Muscadin, E., Bien-Aime, P., Marcelin, L. H., Brown, E. C., & Metalonis, S. W. (2026) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-026-03046-3
Leju, M. Y.-K., & Degu, A. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07156-0
Supportive care, prevention, and emerging therapies for acute chest syndrome in sickle cell disease
Rice, R. R., & Willen, S. M. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2702549
Perspective Chapter: Fetal Hemoglobin Modulators
Walke, V. A. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017037
Mbayabo, G., Lumbala, P. K., Ngole, M., Lumaka, A. Z., Race, V., Matthijs, G., Mikobi, T. M., Devriendt, K., Geet, C. V., & Lukusa-Tshilobo, P. (2026) · eJHaem · doi:10.1002/jha2.70378
Vita, M. V. D., Mwau, M., Omoding, A., Njogu, W., Morino, G., Mulongo, C. M., Aigner, A., & Oevermann, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1889846
Masini, T., Charnaud, S. C., Hankins, J. S., Kityo, C. M., Makani, J., Morris, C. R., Odame, I., Ross, A. L., Segafredo, G., Ubuguyu, O., et al. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(26)00159-8
Al‐Agha, M., AlBadr, F. B., Aleem, A., AlGahtani, F. H., Al-shehri, A., Bashiri, F. A., & Alsultan, A. S. (2026) · British Journal of Haematology · doi:10.1111/bjh.70830
Katumba, A. M., Doree, C. J., & Estcourt, L. J. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012082.pub3
Hydroxyurea benefits for sickle cell anaemia in sub-Saharan Africa
Green, N., & Justman, J. E. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00261-9
Arlet, J., François, L., Jeune, S. L., Bartolucci, P., Habibi, A., & Joseph, L. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.10.001
Metadata
- Authors
- Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., Barredo, J. C., Brown, R. C., Sarnaik, S. A., Howard, T. H., Wynn, L. W., Kutlar, A., Armstrong, F. D., Files, B. A., Goldsmith, J. C., Waclawiw, M. A., Huang, X., & Thompson, B. W.
- Affiliations
- St. Jude Children's Research Hospital (US)
- SUNY Downstate Health Sciences University (US)
- University of Mississippi Medical Center (US)
- Johns Hopkins University (US)
- Children's National (US)
- Howard University (US)
- Duke Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Medical University of South Carolina (US)
- University of Miami (US)
- Children's Hospital of Michigan (US)
- University of Alabama at Birmingham (US)
- Augusta University (US)
- Emory University (US)
- National Heart, Lung, and Blood Institute (US)
- Clinical Trials and Surveys Corporation (US)
- Corresponding author
- Wang, Winfred C
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 377
- Issue
- 9778
- Pages
- 1663-1672
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3133619
- OpenAlex
- W2170086069
- Semantic Scholar
- 007f7341f1586c3f34ecd96fa415bd95116f1c85
- Cited by
- 803
- References
- 35
- Citations by year
- 2026: 46 · 2025: 42 · 2024: 57 · 2023: 49 · 2022: 58 · 2021: 54 · 2020: 58 · 2019: 67 · 2018: 50 · 2017: 64 · 2016: 52 · 2015: 61 · 2014: 50 · 2013: 45 · 2012: 25
- FWCI
- 21.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hb07156-19-0-1, n01hb07159-25-0-1, n01hb07153-18-0-1, n01hb07155-16-0-0, n01hb07158-17-0-0, n01hb07157-15-0-0, n01hb07152-18-0-0, n01hb07151-17-0-0, n01hb07150-20-0-1, n01hb07160-38-0-1, n01hb07154-21-0-0)
- National Heart, Lung, and Blood Institute (N01-HB-07154, N01-HB-07157, N01-HB-07160, N01 HB007155, N01-HB07155, N01-HB-07152, N01-HB-07153, N01 HB007150, N01-HB-07151, N01-HB-07158, N01-HB-07150, N01 HB007160, N01-HB-07159, N01-HB-07156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- hydroxyurea, sickle cell disease, infants, spleen function, renal function, acute chest syndrome, pain episodes, fetal hemoglobin, brain development, mutagenicity, drug toxicity, beta-thalassemia, organ dysfunction, growth, transcranial Doppler, glomerular filtration rate, urine osmolality
- MeSH terms
- Anemia, Sickle Cell, Antisickling Agents, Blood Cell Count, Child Development, Female, Glomerular Filtration Rate, Hemoglobins, Humans, Hydroxyurea, Infant, Male, Osmolar Concentration, Pain, Spleen, United States, Urine, Biomarkers, Technetium Tc 99m Pentetate, Treatment Outcome, Ultrasonography, Doppler, Transcranial, Acute Chest Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
